MDT

97.73

+1.69%↑

A

145.49

-1.42%↓

VEEV

220.23

-3.16%↓

HQY

83.75

+0.5%↑

NEOG

9.26

+0.54%↑

MDT

97.73

+1.69%↑

A

145.49

-1.42%↓

VEEV

220.23

-3.16%↓

HQY

83.75

+0.5%↑

NEOG

9.26

+0.54%↑

MDT

97.73

+1.69%↑

A

145.49

-1.42%↓

VEEV

220.23

-3.16%↓

HQY

83.75

+0.5%↑

NEOG

9.26

+0.54%↑

MDT

97.73

+1.69%↑

A

145.49

-1.42%↓

VEEV

220.23

-3.16%↓

HQY

83.75

+0.5%↑

NEOG

9.26

+0.54%↑

MDT

97.73

+1.69%↑

A

145.49

-1.42%↓

VEEV

220.23

-3.16%↓

HQY

83.75

+0.5%↑

NEOG

9.26

+0.54%↑

Search

Maravai LifeSciences Holdings Inc (Class A)

Cerrado

3.88 -2.76

Resumen

Variación precio

24h

Actual

Mínimo

3.91

Máximo

4

Métricas clave

By Trading Economics

Ingresos

44M

-26M

Ventas

-5.8M

42M

Margen de beneficio

-61.388

Empleados

550

EBITDA

44M

-22M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+7.87% upside

Dividendos

By Dow Jones

Próximas Ganancias

17 mar 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

367M

1.4B

Apertura anterior

6.64

Cierre anterior

3.88

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Maravai LifeSciences Holdings Inc (Class A) Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

14 ene 2026, 22:41 UTC

Adquisiciones, fusiones, absorciones

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 ene 2026, 00:00 UTC

Ganancias

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 ene 2026, 23:47 UTC

Charlas de Mercado

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 ene 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 ene 2026, 23:39 UTC

Charlas de Mercado

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 ene 2026, 23:32 UTC

Charlas de Mercado

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 ene 2026, 22:56 UTC

Adquisiciones, fusiones, absorciones

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 ene 2026, 22:53 UTC

Adquisiciones, fusiones, absorciones

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 ene 2026, 22:17 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 ene 2026, 22:17 UTC

Charlas de Mercado

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 ene 2026, 22:09 UTC

Ganancias

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 ene 2026, 22:08 UTC

Ganancias

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 ene 2026, 22:08 UTC

Ganancias

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 ene 2026, 21:53 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 ene 2026, 21:53 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 ene 2026, 21:52 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Announces Positive Profit Alert for 2025

14 ene 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

Citigroup Acting as Financial Advisor to WuXi XDC

14 ene 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 ene 2026, 21:51 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 ene 2026, 21:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

14 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

14 ene 2026, 21:49 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 ene 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 ene 2026, 21:48 UTC

Adquisiciones, fusiones, absorciones

WuXi XDC Makes Cash Offer for BioDlink International

14 ene 2026, 21:13 UTC

Charlas de Mercado

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 ene 2026, 20:30 UTC

Charlas de Mercado
Ganancias

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 ene 2026, 20:13 UTC

Charlas de Mercado

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 ene 2026, 20:08 UTC

Charlas de Mercado

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 ene 2026, 19:33 UTC

Charlas de Mercado

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 ene 2026, 19:06 UTC

Charlas de Mercado
Ganancias

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Comparación entre iguales

Cambio de precio

Maravai LifeSciences Holdings Inc (Class A) Esperado

Precio Objetivo

By TipRanks

7.87% repunte

Estimación a 12 meses

Media 4.25 USD  7.87%

Máximo 4.5 USD

Mínimo 4 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Maravai LifeSciences Holdings Inc (Class A) Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

3

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.02 / 2.115Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

No Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
help-icon Live chat